

JC06 Rec'd PCT/PTO 17 MAY 2005  
MAIL STOP PCT  
10/531462

Docket No. 270280US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Mauro NAPOLETANO, et al.

SERIAL NO: 10/531,462

GAU:

FILED: April 15, 2005

EXAMINER:

FOR: 9A-AZALIDES WITH ANTI-INFLAMMATORY ACTIVITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Surinder Sachar

Norman F. Oblon  
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar  
Registration No. 34,423

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 270280US0PCT	SERIAL NO. 10/531,462
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Mauro NAPOLETANO, et al.	
		FILING DATE April 15, 2005	GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA 4,886,792	12/12/89	DJOKIC, Slobodan et al.			
	AB 3,478,014	11/11/69	DJOKIC, Slobodan et al.			
	AC 3,928,387	12/23/75	KIERSTEAD, Richard Wightman et al.			
	AD 4,328,334	05/04/82	KOBREHEL, Gabrijela et al.			
	AE 4,464,527	08/07/84	BRIGHT, Gene M.			
	AF 5,250,518	10/02/93	KOBREHEL, Gabrijela et al.			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
AG	00/42055	07/20/00	WO		NO
AH	0 775 489	05/28/97	EP		NO
AI	0 771 564	05/07/97	EP		NO
AJ	92/16226	10/01/92	WO		NO
AK	20010301	04/27/01	HR(Equivalent of WO 02/087596)		NO
AL	892,357	07/01/82	BE		NO

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AM	M. T. LABRO: "Anti-inflammatory activity of macrolides: a new therapeutic potential? JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, Vol. 41, Suppl. B, pages 37-46, 1998.	
AN	Jun TAMAOKI: "Effect of Erythromycin on Endotoxin-induced Microvascular Leakage in the Rat Trachea and Lungs" Am. J. Respir. Crit. Care Med., Vol. 151, pages 1582-1588, 1995.	
AO	Vera M. KEATINGS: "Differences in Interleukin-8 and Tumor Necrosis Factor- $\alpha$ in Induced Sputum from Patients with Chronic Obstructive Pulmonary Disease or Asthma" Am. J. Respir. Crit. Care Med., Vol. 153, pages 530-534, 1996.	
AP	Hajime TAKIZAWA: "Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells" Am. J. Respir. Crit. Care Med., Vol. 156, pages 266-271, 1997.	
AQ	Hiroyuki MIYATAKE et al.: "Erythromycin Reduces the Severity of Bronchial Hyperresponsiveness in Asthma" CHEST, Vol. 99, pages 670-673, 1991.	
AR	Peter J. Barnes: "Mechanisms in COPD, Differences From Asthma" CHEST, Vol. 117, 2 Suppl., pages 10S-14S, 2000.	
AS	Tomoko SUZUKI: "Erythromycin and Common Cold in COPD" CHEST, Vol. 120, pages 730-733, 2001.	
AT	Maric Therese LABRO: "Immunomodulatory Actions of Antibacterial Agents" Clin. Immunother., Vol. 6, pages 454-464, 1996.	
AU	Slobodan DJOKIC et al.: "Erythromycin Series. Part 11. Ring Expansion of Erythromycin A Oxime by the Beckmann Rearrangement" J. Chem. Soc. Perkin Trans., pages 1881-1890, 1986.	
AV	Viera STVRTINOVA, Jan JAKUBOVSKY and Ivan HULIN: "INFLAMMATION AND FEVER" Academic Electronic Press, 1995.	
AW	Ronald ANDERSON: "MEMBRANE-STABILIZING, ANTI-INFLAMMATORY INTERACTIONS OF MACROLIDES WITH HUMAN NEUTROPHILS" Inflammation, Vol. 20, No. 6, pages 693-705, 1996.	
AX	Edwin H. FLYNN: "Erythromycin. I. Properties and Degradation Studies" J. Am. Chem. Soc., Vol. 76, pages 3121-3131, 1954.	
AY	Jean-Claude GASC ET AL.: "NEW ETHER OXIME DERIVATIVES OF ERYTHROMYCIN A, A STRUCTURE-ACTIVITY RELATIONSHIP STUDY" The Journal of Antibiotics, Vol. 44, pages 313-330, 1991.	<input checked="" type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
		ATTY DOCKET NO. 271362US6PCT	SERIAL NO. 10/531,462
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Takeshi SHIMOYAMA	
		FILING DATE April 15, 2005	GROUP
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)			
AZ	Crystal C. KOCH: "Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of <i>Streptococcus pneumoniae</i> " <i>Journal of Antimicrobial Chemotherapy</i> , vol. 46, pages 19-26, 2000.		
AAA	Melita ZUNIC: "MDP(Lysyl)GDP, a Nontoxic Muramyl Dipeptide Derivative, Inhibits Cytokine Production by Activated Macrophages and Protects Mice from Phorbol Ester- and Oxazolone-Induced Inflammation" <i>The Society for Investigative Dermatology, Inc.</i> , Vol. 111, No. 1, pages 77-82, 1998.		
AAB	Shin-ichi KONNO: "INHIBITION OF HUMAN T-LYMPHOCYTE ACTIVATION BY MACROLIDE ANTIBIOTIC, ROXITHROMYCIN" <i>Life Sciences</i> , Vol. 51, pages PL 231-236, 1992.		
AAC	Patrick R. MURRAY, Ellen Jo BARON, Michael A. PFALLER, Fred C. TENOVER and Robert H. YOLKEN: "Manual of CLINICAL MICROBIOLOGY" <i>American Society for Microbiology</i> , 7 <sup>th</sup> Edition, 1999.		
AAD	Houria ABDELGHAFFAR: "Erythromycin A-Derived Macrolides Modify the Functional Activities of Human Neutrophils by Altering the Phospholipase D-Phosphatidate Phosphohydrolase Transduction Pathway" <i>The Journal of Immunology</i> , vol. 159, pages 3395-4005, 1997.		
AAF	Adam JAFFE: "Long-term azithromycin may improve lung function in children with cystic fibrosis" <i>The Lancet</i> , vol. 351, page 420, February 7, 1998.		
AAF	The Merck Index, XIII edition, No. 917, page 159, 2001.		
AAG	Hiroshi KOYAMA, Duncan M. GEDDES: "Erythromycin and diffuse panbronchiolitis" <i>Thorax</i> , vol. 52, pages 915-918, 1997.		
AAH			
AAI			
AAJ			
AAK			
AAL			
AAM			
AAN			
AAO			
AAP			
Examiner		Date Considered	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			